CTF13 Antibody

What is CTF13 and why is it significant for kinetochore research?

CTF13 is an essential protein component of the CBF3 kinetochore complex in Saccharomyces cerevisiae (budding yeast). It encodes a predicted 478 amino acid protein with no homology to known proteins, making it a unique component of the kinetochore assembly . CTF13 plays a critical role in chromosome segregation, with ctf13 mutants exhibiting chromosome missegregation at permissive temperature and transient arrest at nonpermissive temperature as large-budded cells with G2 DNA content and a short spindle .

The significance of CTF13 lies in its central position within the kinetochore structure. Genetic and biochemical data indicate that CTF13 is an essential kinetochore protein required for proper centromere function . Methodologically, antibodies against CTF13 serve as valuable tools for investigating kinetochore architecture, as demonstrated by experiments where antibodies recognizing epitope-tagged CTF13 protein altered the electrophoretic mobility of CEN DNA-protein complexes formed in vitro .

From an experimental standpoint, CTF13 provides a unique entry point for studying kinetochore assembly and function, as it forms a critical interface between the fundamental CBF3 complex and other kinetochore components through its interactions with multiple proteins.

How does CTF13 function within the CBF3 complex?

CTF13 functions as part of the CBF3 complex, which is composed of at least four proteins: Ndc10p/CTF14, Cep3p, CTF13p, and Skp1p . Within this complex, CTF13 forms a heterodimer with Skp1p, which serves as a crucial building block for the assembly of the complete CBF3 complex . This heterodimer interacts with Ndc10p and Cep3p to bind centromere DNA (CEN DNA).

The specific residues Y139 and N140 of Skp1 are essential for the interaction with CTF13 and subsequent CBF3 complex formation . When these residues are mutated (Y139K, N140K), the complex fails to form properly, highlighting the precision required for this protein-protein interaction . Interestingly, these same residues of Skp1 are also essential for SCF ligase formation, suggesting a common binding interface used in different cellular contexts .

Methodologically, in vitro reconstitution experiments have demonstrated that the majority (97%) of purified CTF13p/Skp1p heterodimer can bind to a centromere DNA affinity matrix, while only 24% binds to a control matrix carrying nonfunctional centromere DNA . This indicates that the CTF13-Skp1p heterodimer maintains specificity for functional centromere sequences, a critical feature for proper kinetochore assembly.

What approaches can be used to validate CTF13 antibody specificity?

Validating antibody specificity is crucial for reliable experimental outcomes when working with CTF13 antibodies. Several methodological approaches can be employed to ensure specificity:

Epitope tagging provides a powerful validation strategy for CTF13 antibodies. By engineering yeast strains expressing epitope-tagged CTF13 (e.g., HA, Myc, or Strep tags), researchers can compare signals obtained with CTF13-specific antibodies to those obtained with well-characterized tag-specific antibodies . This approach has been successfully used with other kinetochore proteins, where triple HA-tagged proteins were detected by Western blot to confirm complex formation .

Genetic approaches offer another validation method. Since CTF13 is an essential gene, conditional mutants (such as temperature-sensitive alleles like ctf13-30) can be utilized to confirm antibody specificity by observing diminished signals under restrictive conditions . Comparison of signals in wild-type versus mutant backgrounds provides evidence of specificity.

Complementary biochemical techniques can further validate specificity. For instance, if CTF13 antibodies are used in immunoprecipitation experiments, the precipitated material should contain known interacting partners such as Skp1p, which can be confirmed by Western blotting . Additionally, the antibody should recognize a protein of the expected molecular weight (predicted to be around 55 kDa for CTF13) on Western blots.

For assessing functional relevance, experiments similar to those showing that "antibodies recognizing epitope-tagged CTF13 protein decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro" can confirm that the antibody recognizes the functional form of CTF13 involved in centromere binding .

How can CTF13 antibodies be used to study kinetochore assembly dynamics?

CTF13 antibodies offer valuable tools for investigating the complex process of kinetochore assembly. Several advanced methodological approaches can be employed:

Chromatin immunoprecipitation (ChIP) using CTF13 antibodies allows researchers to monitor the kinetics of CTF13 recruitment to centromere DNA throughout the cell cycle. Similar approaches with related kinetochore proteins have successfully demonstrated centromere association, using specific primers for centromere regions (e.g., CEN3, CEN8) and non-centromeric controls (e.g., PGK1) . When designing such experiments, it's important to titrate templates for both total chromatin and immunoprecipitate to determine the linear range for PCR amplification .

Immunoprecipitation combined with mass spectrometry can reveal the composition of CTF13-containing complexes at different cell cycle stages. This approach has been used to identify phosphorylation states of CTF13p and Skp1p , and could be extended to identify other post-translational modifications or novel interacting partners under different cellular conditions.

Live-cell imaging using antibody-based techniques can track the dynamic localization of CTF13 relative to other kinetochore components. While the search results don't specifically mention fluorescence-based approaches for CTF13, epitope-tagged CTF13 could be visualized using fluorescently labeled tag-specific antibodies in fixed cells or with genetically encoded fluorescent proteins in live cells.

Biochemical reconstitution experiments can be complemented with CTF13 antibodies to validate in vitro observations. For example, adding CTF13 antibodies to reconstitution reactions could help determine the step at which CTF13 functions in the assembly pathway, similar to experiments showing altered electrophoretic mobility of CEN DNA-protein complexes .

What is the relationship between CTF13 and other kinetochore complexes?

The relationship between CTF13 (as part of the CBF3 complex) and other kinetochore complexes reveals a hierarchical organization with both direct and indirect interactions:

Genetic interaction studies provide compelling evidence for functional relationships between CTF13 and outer kinetochore components. Deletion of genes encoding the Ctf3 complex proteins (Ctf3p, Mcm22p, Mcm16p) or Ctf19p is synthetically lethal when combined with a ctf14-42 (ndc10) mutation . Additionally, these deletions lower the non-permissive temperature of ctf13-30 mutants from 35°C to 32°C . These genetic interactions suggest that when inner kinetochore function is compromised, the outer kinetochore becomes essential for cell viability.

Biochemical studies indicate a bridge-like connection between complexes. While direct biochemical interactions between the Ctf3 complex and CBF3 components (including CTF13) could not be detected by co-immunoprecipitation, Ctf19p appears to interact with both complexes . This suggests that Ctf19p may serve as a linker between the inner kinetochore (containing CBF3/CTF13) and the outer kinetochore components.

Chromatin immunoprecipitation experiments demonstrate that Ctf3p, Mcm22p, and Mcm16p association with centromere DNA depends on functional Ctf19p . This hierarchical dependency suggests that CTF13, as part of the inner kinetochore CBF3 complex, likely establishes the foundation for subsequent recruitment of Ctf19p and the Ctf3 complex to centromeres.

How can CTF13 antibodies be used to investigate post-translational modifications?

CTF13 antibodies can be powerful tools for investigating post-translational modifications, particularly phosphorylation, which has been detected on CTF13 :

Phospho-specific antibodies could be developed to recognize specific phosphorylated residues of CTF13. While the search results don't mention specific phosphorylation sites, mass spectrometry analysis has detected phosphate groups on CTF13p . Antibodies raised against these phosphorylated residues would allow researchers to monitor the phosphorylation status of CTF13 under different conditions or in various mutant backgrounds.

For comparative phosphorylation analysis, CTF13 can be immunoprecipitated from cells under different conditions (e.g., different cell cycle stages or in response to various stressors), followed by treatment with or without phosphatase. The samples can then be analyzed by Western blotting using standard CTF13 antibodies to detect mobility shifts associated with phosphorylation status . This approach has already revealed that dephosphorylated CTF13p/Skp1p remains capable of forming CBF3-centromere DNA complexes in vitro .

Functional studies can be designed to determine the significance of CTF13 phosphorylation. Although current evidence suggests that "phosphate groups detected on S. cerevisiae-Ctf13p and Skp1p are not required for the formation of CBF3-centromere DNA complexes in vitro" , phosphorylation might play roles in other aspects of CTF13 function. CTF13 antibodies could be used in ChIP experiments to compare centromere association of wild-type versus phospho-mutant CTF13.

Mass spectrometry coupled with immunoprecipitation using CTF13 antibodies allows precise identification of modified residues and quantification of modification stoichiometry. This approach can reveal not only phosphorylation but also other post-translational modifications that might regulate CTF13 function.

What controls are essential when using CTF13 antibodies in chromatin immunoprecipitation?

Chromatin immunoprecipitation (ChIP) with CTF13 antibodies requires careful design and multiple controls to ensure reliable and interpretable results:

Specificity controls are fundamental to validate ChIP results. These should include immunoprecipitation with non-specific IgG antibodies and, where possible, ChIP in strains with reduced CTF13 expression (although complete deletion would be lethal) . For epitope-tagged CTF13, an untagged strain serves as an appropriate negative control, as demonstrated for other kinetochore proteins .

Input normalization is essential for quantitative comparisons. A portion of the chromatin sample prior to immunoprecipitation (typically 1-5%) should be processed in parallel as the "input" control. This accounts for differences in starting material and helps normalize ChIP signals across samples.

Primer selection requires both positive and negative genomic regions. Centromeric regions (e.g., CEN3, CEN8) serve as positive targets for CTF13 binding, while non-centromeric regions (e.g., PGK1) provide negative controls . The linear range for PCR amplification should be determined by titrating templates for both total chromatin and immunoprecipitate .

Experimental validation can be achieved through complementary approaches. If possible, performing parallel ChIP experiments with antibodies against known CTF13-interacting proteins (e.g., Ndc10p, Cep3p) should show enrichment of the same genomic regions. Additionally, using epitope-tagged CTF13 and corresponding tag antibodies can provide confirmation of results obtained with CTF13-specific antibodies.

Cell cycle synchronization may be necessary to detect temporal changes in CTF13 binding. Since kinetochore assembly is cell cycle-regulated, synchronizing cells (e.g., with alpha-factor, hydroxyurea, or nocodazole) can reveal stage-specific binding patterns and prevent misinterpretation of results from mixed populations.

How can CTF13 antibodies be used to investigate protein complex assembly in vitro?

CTF13 antibodies offer valuable tools for dissecting the stepwise assembly of kinetochore complexes in vitro:

Immunodepletion experiments can determine the requirement for CTF13 in specific biochemical processes. By using CTF13 antibodies to deplete the protein from cellular extracts before in vitro reconstitution experiments, researchers can assess which aspects of kinetochore assembly depend on CTF13.

Electrophoretic mobility shift assays (EMSAs) combined with CTF13 antibodies can identify specific protein-DNA complexes. As demonstrated in the literature, "antibodies recognizing epitope-tagged CTF13 protein decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro" . This approach, sometimes called a "supershift" assay, can confirm the presence of CTF13 in DNA-binding complexes.

Order-of-addition experiments can determine the assembly sequence of the CBF3 complex. By adding CTF13 antibodies at different stages of CBF3 complex assembly, researchers can determine when CTF13 incorporation occurs and whether it remains accessible to antibodies in the fully assembled complex.

Pull-down assays using immobilized antibodies can isolate native complexes. CTF13 antibodies coupled to a solid support (e.g., protein A/G beads) can be used to isolate intact complexes from cell extracts, which can then be analyzed for composition or used in functional assays. This approach has been successful with other kinetochore proteins .

Reconstitution with mutant components can be monitored using CTF13 antibodies. For example, experiments showing that Skp1 mutations (N139K, Y140K) prevent CBF3 complex formation relied on detection of complex components (including Skp1) with antibodies . Similar approaches could be used to test the effect of CTF13 mutations on complex assembly.

What experimental approaches can distinguish between direct and indirect CTF13 interactions?

Distinguishing between direct and indirect protein interactions involving CTF13 requires specialized experimental approaches:

In vitro binding assays with purified components provide the strongest evidence for direct interactions. Experiments using purified HisCtf13p/HisSkp1p heterodimer, Ndc10p, Cep3p, and CEN3 DNA have demonstrated the direct involvement of these components in complex formation . Similar approaches can test whether newly identified interacting partners bind directly to CTF13 or require additional proteins.

Yeast two-hybrid screening can detect binary protein interactions. While not mentioned specifically for CTF13 in the search results, genome-wide two-hybrid screens have been used successfully to identify interactions between other kinetochore proteins . This approach could reveal direct binding partners of CTF13.

Cross-linking coupled with mass spectrometry (CXMS) can map interaction interfaces at the amino acid level. By chemically cross-linking protein complexes containing CTF13 and analyzing the cross-linked peptides by mass spectrometry, researchers can identify amino acids that are in close proximity, suggesting direct contact sites.

Sequential immunoprecipitation (also called tandem affinity purification) can identify stable subcomplexes. By performing a first immunoprecipitation with CTF13 antibodies, followed by a second immunoprecipitation with antibodies against a suspected interacting protein, researchers can isolate complexes containing both proteins, indicating a stable (though not necessarily direct) interaction.

Genetic interaction mapping provides complementary evidence for functional relationships. As shown in the search results, genes encoding the Ctf3 complex proteins (Ctf3p, Mcm22p, Mcm16p) show synthetic lethality with ctf13-30 mutations . While these genetic interactions suggest functional relationships, they must be combined with biochemical data to distinguish direct from indirect physical interactions.

How can researchers interpret discrepancies between different CTF13 antibody detection methods?

When faced with discrepancies between different detection methods using CTF13 antibodies, systematic analysis is essential:

Epitope accessibility varies across techniques. In Western blotting, proteins are denatured, exposing most epitopes, whereas in techniques like ChIP or immunoprecipitation, proteins retain their native conformation and interactions. This fundamental difference can lead to discrepancies where an antibody works well in one application but poorly in another. For instance, if a CTF13 epitope is masked by interaction with Skp1p , an antibody targeting this region might fail in co-immunoprecipitation while succeeding in Western blotting.

Complex stability affects detection in native conditions. The CBF3 complex, which includes CTF13, may be stable under certain buffer conditions but dissociate in others. This could lead to inconsistent results when using different extraction or immunoprecipitation buffers. The search results indicate that specific residues of Skp1 (Y139, N140) are essential for stable complex formation , suggesting that particular protein-protein interactions are critical for maintaining the complex.

Post-translational modifications can alter antibody recognition. CTF13 is known to be phosphorylated , and this modification might affect epitope recognition by certain antibodies. Researchers should consider whether discrepancies correlate with conditions that might alter CTF13's modification state, such as cell cycle stage or growth conditions.

To resolve discrepancies, researchers should:

• Compare results using multiple antibodies targeting different CTF13 epitopes

• Validate with epitope-tagged versions of CTF13 and tag-specific antibodies

• Test different extraction and binding conditions to optimize for each technique

• Consider whether the discrepancy itself reveals biologically meaningful information about CTF13 conformation or interactions

What challenges exist in interpreting CTF13 antibody data from temperature-sensitive mutants?

Interpreting CTF13 antibody data from temperature-sensitive mutants presents several methodological challenges:

Protein conformational changes at restrictive temperatures may directly affect antibody binding independent of protein levels. Temperature-sensitive mutations often cause protein misfolding at the non-permissive temperature, potentially masking or exposing epitopes recognized by the antibody. This could lead to apparent changes in signal that reflect altered antibody access rather than genuine changes in protein abundance or localization.

Degradation kinetics vary between mutants. Some temperature-sensitive mutants (like ctf13-30) may be rapidly degraded upon shift to the non-permissive temperature, while others may persist in a non-functional state. The search results indicate that ctf13 mutants "transiently arrest at nonpermissive temperature as large-budded cells with a G2 DNA content and a short spindle" , suggesting that downstream cellular processes are affected before complete protein degradation occurs.

Genetic interactions complicate interpretation. The search results show that deleting genes like CTF3, MCM22, MCM16, or CTF19 in a ctf13-30 background lowers the non-permissive temperature from 35°C to 32°C . These interactions suggest that the phenotype of ctf13 mutants depends on the status of other genes, which must be considered when interpreting antibody data.

To address these challenges, researchers should:

• Include time-course experiments after temperature shift to distinguish immediate from secondary effects

• Compare multiple temperature-sensitive alleles of CTF13 to identify allele-specific versus general effects

• Use epitope-tagged wild-type CTF13 as an internal control under identical conditions

• Complement antibody-based approaches with functional assays to correlate protein detection with activity

How should researchers interpret CTF13 phosphorylation data in the context of functional studies?

The interpretation of CTF13 phosphorylation data requires careful consideration of both biochemical and functional evidence:

Quantitative considerations matter for phosphorylation analysis. The search results note that if active Ctf13p/Skp1p contains phosphate residues not removed by phosphatase treatment, "this active form should only comprise a small fraction of the total protein because it was not detected by mass spectrometry" . This emphasizes the importance of quantitative measurements when assessing the functional relevance of phosphorylation.

Experimental context affects interpretation of phosphorylation data. The in vitro assays described in the search results specifically tested CBF3-centromere DNA complex formation . Phosphorylation might play roles in other aspects of CTF13 function not captured by this assay, such as protein stability, subcellular localization, or interactions with regulatory factors.

Multiple approaches strengthen phosphorylation data interpretation:

• Combine mass spectrometry identification of phosphorylation sites with mutational analysis (phospho-mimetic and phospho-deficient mutations)

• Compare phosphorylation status across different cellular conditions (cell cycle stages, stress responses)

• Use phospho-specific antibodies (if available) to track specific phosphorylation events in vivo

• Correlate phosphorylation status with multiple functional outputs beyond complex formation

The search results provide strong evidence that the observed phosphorylation is not required for one specific function (in vitro complex formation) , but researchers should remain open to phosphorylation playing roles in other aspects of CTF13 biology.

What is the evidence for CTF13's role as an essential kinetochore protein?

Multiple lines of evidence establish CTF13 as an essential component of the kinetochore:

Genetic evidence demonstrates the essential nature of CTF13. The CTF13 gene is essential for cell viability, and temperature-sensitive ctf13 mutants exhibit chromosome missegregation at permissive temperature . At non-permissive temperature, these mutants transiently arrest as large-budded cells with G2 DNA content and a short spindle , a phenotype consistent with defective kinetochore function leading to spindle assembly checkpoint activation.

Biochemical evidence confirms CTF13's direct involvement in kinetochore-centromere interaction. The ability of antibodies recognizing epitope-tagged CTF13 to decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro provides direct evidence for CTF13's presence in centromere-binding complexes . Furthermore, purified HisCtf13p/HisSkp1p heterodimer binds specifically to functional centromere DNA, with 97% binding to a centromere DNA affinity matrix compared to only 24% binding to a control matrix carrying nonfunctional centromere DNA .

Structural evidence places CTF13 at the core of kinetochore architecture. As part of the CBF3 complex, CTF13 forms a heterodimer with Skp1p, which then interacts with Ndc10p and Cep3p to form the complete complex . Specific residues of Skp1 (Y139, N140) are essential for this interaction , highlighting the precise molecular requirements for proper complex assembly.

Synthetic genetic interactions further support CTF13's central role. The synthetic lethality observed when combining ctf14-42 (ndc10) mutations with deletions of genes encoding outer kinetochore components (CTF3, MCM22, MCM16, CTF19) suggests that when inner kinetochore function (where CTF13 operates) is compromised, the outer kinetochore becomes essential for cell viability.

How has our understanding of CTF13 function evolved through antibody-based research?

Antibody-based research has played a crucial role in advancing our understanding of CTF13 function:

Early characterization established CTF13 as a centromere-binding protein. The finding that "antibodies recognizing epitope-tagged CTF13 protein decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro" provided early evidence that CTF13 is directly involved in the protein-DNA interactions at the centromere. This fundamental observation helped establish CTF13 as an essential kinetochore component.

Biochemical reconstitution revealed the molecular organization of CTF13-containing complexes. Using purified components, researchers demonstrated that CTF13 forms a heterodimer with Skp1p, which then associates with Ndc10p and Cep3p to form the CBF3 complex that binds centromere DNA . Antibody detection was essential for monitoring the presence of these proteins during purification and reconstitution experiments.

Post-translational modification studies clarified regulatory mechanisms. Mass spectrometry combined with functional assays revealed that CTF13 is phosphorylated, but these phosphate groups are not required for CBF3-centromere DNA complex formation in vitro . This unexpected finding demonstrated that certain aspects of CTF13 function are phosphorylation-independent, contrary to what might have been assumed.

Hierarchical organization of the kinetochore was mapped through combined approaches. While direct biochemical interactions between the CBF3 complex (containing CTF13) and the Ctf3 complex could not be detected by co-immunoprecipitation, genetic evidence revealed functional relationships . This combination of negative biochemical data and positive genetic data suggested an indirect connection between these complexes, likely mediated by intermediate proteins like Ctf19p .

Future antibody-based research directions might include:

• Development of phospho-specific CTF13 antibodies to investigate the temporal and spatial regulation of CTF13 phosphorylation

• Combined immunoprecipitation and crosslinking approaches to capture transient interactions

• Super-resolution microscopy using CTF13 antibodies to visualize kinetochore ultrastructure

What are the methodological considerations for developing new CTF13 antibodies?

Developing effective new CTF13 antibodies requires careful consideration of several methodological factors:

Epitope selection is critical for antibody functionality. Researchers should avoid regions of CTF13 that are likely involved in protein-protein interactions, such as the Skp1-binding interface, as these may be inaccessible in the native complex. Instead, target regions that are likely exposed on the protein surface. Structural data on the CBF3 complex would be valuable for this purpose, though the search results don't mention if such data exists specifically for CTF13 .

Antigen preparation options include both peptide and recombinant protein approaches. Short synthetic peptides corresponding to selected CTF13 epitopes can be used for immunization. Alternatively, recombinant fragments or full-length CTF13 can be produced, though this may be challenging as the search results indicate that CTF13 is typically purified as a heterodimer with Skp1p . The HisCtf13p/HisSkp1p heterodimer described in the literature could potentially serve as an antigen for antibody production.

Validation strategies should encompass multiple techniques. New CTF13 antibodies should be validated by Western blotting against extracts from wild-type strains versus strains with altered CTF13 expression (e.g., temperature-sensitive mutants at permissive and non-permissive temperatures). Additionally, immunoprecipitation followed by mass spectrometry should confirm the ability to pull down CTF13 and its known interacting partners such as Skp1p, Ndc10p, and Cep3p .

Application-specific testing is essential. For ChIP applications, new antibodies should be tested for their ability to immunoprecipitate centromere DNA but not non-centromeric regions, similar to experiments described for other kinetochore proteins . For biochemical applications, antibodies should be tested for their ability to recognize native CTF13 in complex with other proteins and possibly alter complex mobility in gel shift assays .

Species considerations may affect experimental design. Since most CTF13 research focuses on budding yeast (S. cerevisiae), antibodies should be raised in species distantly related to yeast (typically rabbit, mouse, or rat) to minimize cross-reactivity with other yeast proteins. Cross-reactivity testing against extracts from CTF13-depleted cells is advisable to ensure specificity.